Cost-effectiveness analysis of fidaxomicin versus vancomycin in Clostridium difficile infection.

ABSTRACT:

Objectives

Fidaxomicin was non-inferior to vancomycin with respect to clinical cure rates in the treatment of Clostridium difficile infections (CDIs) in two Phase III trials, but was associated with significantly fewer recurrences than vancomycin. This economic analysis investigated the cost-effectiveness of fidaxomicin compared with vancomycin in patients with severe CDI and in patients with their first CDI recurrence.

Methods

A 1 year time horizon Markov model with seven health states was developed from the perspective of Scottish public healthcare providers. Model inputs for effectiveness, resource use, direct costs and utilities were obtained from published sources and a Scottish expert panel. The main model outcome was the incremental cost-effectiveness ratio (ICER), ex

SUBMITTER: Nathwani D 

PROVIDER: S-EPMC4195473 | biostudies-literature | 2014 Nov

REPOSITORIES: biostudies-literature